Results 191 to 200 of about 27,854 (272)

Evolution of Multitarget Strategies for Alzheimer's Disease: From Cholinergic Inhibition to Network-Oriented Therapeutic Design (2006-2025). [PDF]

open access: yesPharmaceuticals (Basel)
Mella J   +10 more
europepmc   +1 more source

Histone Modifications at the Intersection of Aging, Neuroinflammation and Metabolism in Alzheimer's Disease

open access: yesAging Cell, Volume 25, Issue 11, November 2026.
This review examines how histone modifications integrate aging, metabolic dysfunction and neuroinflammation to shape persistent, cell‐type‐specific chromatin states in Alzheimer's disease. By distinguishing causal regulation from association through perturbation, persistence and reversibility, it highlights metabolic–epigenetic feedback loops and ...
Junyi Liang   +7 more
wiley   +1 more source

The 2027 BCPT Perspectives on Studies Involving Natural Products, Traditional Chinese Medicine and Systems Pharmacology

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Natural products, including isolated compounds, complex extracts, traditional medicinal preparations and marine, microbial, fungal and animal‐derived materials, remain important sources of therapeutic agents and pharmacological discovery.
Pernille Tveden‐Nyborg   +4 more
wiley   +1 more source

Research Progress on the Multitarget Mechanisms of Terpenoids in the Treatment of Ischemic Stroke. [PDF]

open access: yesStroke Res Treat
Yang J   +11 more
europepmc   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Medicinal Chemistry Aspects of Thiazole and Thiazolidine Derivatives as Fundamental Building Blocks to Design New NNRTIs Against HIV‐1 Reverse Transcriptase

open access: yesChemMedChem, Volume 21, Issue 19, 14 October 2026.
HIV‐1 reverse transcriptase (HIV‐1 RT) is a polymerase enzyme and a key target in HIV‐1 therapy. The discovery of selective HIV‐1 RT inhibitors has highlighted thiazole scaffolds and their derivatives, thiazolidine‐2‐one and thiazolidine‐2,4‐dione, as promising structures for the rational design of novel non‐nucleoside reverse transcriptase inhibitors (
José Arion da Silva Moura   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy